What smart money is saying about DexCom
7 funds in our archive have pitched DexCom, most recently Goodhart Partners Global Future Leaders Fund in September 2026.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
8 lettersToo few moves on DexCom yet for a clear signal
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 10 fund letters reported a position in DexCom, with 2 buys (opened or added) and 4 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 6 | 2 | 0 | 2 |
| Q1 2026 | 0 | 0 | 0 | 1 |
| Q4 2025 | 2 | 0 | 2 | 2 |
| Q3 2025 | 1 | 0 | 1 | 2 |
| Q4 2024 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 10 positions · 6 moves
- September 2026
“DexCom, a manufacturer of blood glucose monitors, shows where the long-term opportunity lies.”
DexCom - September 2026
“For Dexcom and Illumina , earlier weakness reflected genuine operational difficulties, so patience required evidence that execution was improving. Dexcom, whose continuous glucose monitors help people manage diabetes, has consistently delivered margin improvement and accelerating patient additions as it continues to expand the use of its technology across new patient populations.”
DexCom - September 2026
“For Dexcom and Illumina , earlier weakness reflected genuine operational difficulties, so patience required evidence that execution was improving.”
DexCom - New positionLiontrust US Opportunities FundSeptember 2026
“There was some repositioning in healthcare where we initiated new positions in DexCom and Boston Scientific, and reinstated Intuitive Surgical after its T score improved.”
DexCom - New positionLiontrust Balanced FundSeptember 2026
“Portfolio Changes We continued to refine the portfolio around a number of high-conviction positions whilst maintaining our focus on businesses benefiting from long-term structural growth trends.”
DexCom - July 2026
“Our holdings in Dexcom and IQVIA were the strongest examples of this, after reporting solid earnings and allaying some of the concerns which we felt were unjustified.”
DexCom - December 2025
“We sold Dexcom to help fund our purchase of argenx.”
DexCom - December 2025
“We exited our position in Dexcom in November.”
DexCom - September 2025
“Along with Atlassian, we also ended our investment campaigns in Dexcom and LPL Financial during the quarter. Dexcom is a leader in continuous glucose monitoring, with strong market penetration in Type 1 diabetes and increasing traction in Type 2 diabetes (T2D). While we continue to view the T2D opportunity as significant, Dexcom has faced several operational challenges in recent years and continues to face strong competition from Abbott, whose cost- effective FreeStyle Libre platform is well positioned in the T2D segment. As a result, we exited our position in favor of companies with higher conviction profit cycles and more compelling valuations.”
DexCom - ExitedFocus GrowthDecember 2024
“Recent Portfolio Activity The table below shows all buys and sells completed during the quarter, followed by a brief rationale. Buys Sells Eli Lilly DexCom Buys Eli Lilly Eli Lilly is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S. from its leading drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment: human pharmaceutical products. Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology, immunology and central nervous system disorders. Currently, there are two phase-three assets: orforglipron, an oral GLP-1, and retatrutide, a triple incretin agonist, which could possibly expand upon the potential success of Mounjaro. We believe that Mounjaro has the potential to commercialize beyond Type 2 diabetes and obesity, potentially in the areas of heart disease, sleep apnea, fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile. Sells Dexcom We sold Dexcom after the surprisingly weak second quarter earnings report and only a modest recovery in the third quarter.”
DexCom
Fund coverage · 7 theses
- Goodhart Partners Global Future Leaders FundSeptember 2026
DexCom is viewed as a long-term healthcare opportunity expanding from type 1 diabetes into much larger type 2 and wellness markets.
Read the full thesis - Liontrust Balanced FundSeptember 2026
DexCom offers exposure to the long-term adoption of continuous glucose monitoring.
Read the full thesis - Alpha Wealth FundsMarch 2026
DexCom is a leading CGM company targeting large Type 2 diabetes expansion and Medicare coverage for significant long-term growth.
Read the full thesis - Aristotle Large Cap GrowthDecember 2025
DexCom is a leading CGM company with low market penetration, strong reimbursement, and new products supporting sustained double-digit growth and a justified premium.
Read the full thesis - Aristotle Focus GrowthDecember 2025
DexCom is a CGM leader with favorable reimbursement, product innovation, and large untapped markets supporting sustained growth at a justified premium valuation.
Read the full thesis - Aristotle Core EquitySeptember 2025
Dexcom is a strong investment opportunity in the medical device sector, specializing in continuous glucose monitoring systems with significant growth potential and a solid financial foundation.
Read the full thesis - Bell Global Equities FundAugust 2025
Dexcom is a fast-growing US MedTech company specializing in continuous glucose monitoring systems, poised for significant growth due to its strong market position and expanding opportunities in type 2 diabetes management.
Read the full thesis
Read every full thesis on DexCom
Read all 7 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→